to assess safety and efficacy of high-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency syndromes we treated a group of 19 patients with a monthly dose of 400 mg/kg of reduced and alkylated , maltose-containing immunoglobulin ( gamimune , cutter biological , berkeley , california ) and compared their responses with a group of 16 patients receiving 100 mg/kg per month intravenously .
C0085297
intravenous immunoglobulin
C0021027
immunoglobulin